Philogen IPO a No-Go After Bayer Nixes Antibody Deal
By Nuala Moran
Friday, February 18, 2011
LONDON Philogen SpA pulled its initial public offering on the Milan Stock Exchange after partner Bayer Schering Pharma AG peremptorily terminated a licensing and collaboration deal between the two for the development of vascular-targeting antibodies in the treatment of cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.